Please assess the completion status of the following clinical trial:

Trial Title: Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Naïve patients with wet AMD(age-related macular degeneration) treated with Eylea (in accordance with the local Summary of Product Characteristics, SPC).~Exclusion Criteria:~* Exclusion criteria as listed in the local SPC. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.~* Any concomitant therapy with another agent to treat wet AMD in the study eye.~* Any prior or concomitant therapy with another drug for wAMD.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: None): According to the recommendations of the Summary of Product Characteristics (SmPC) in Italy

Based on this trial design, predict the completion outcome and termination type (if applicable).